DUBLIN--(BUSINESS WIRE)--The "Global Biological Safety Testing Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023" report has been added to Research and Markets' offering.
The global biological safety testing market is expected to grow at the CAGR of 13% during the forecast period of 2016-2023.
Drug launches in recent years mainly contributes to the growth of the global biological safety testing market during the forecast period. However, high healthcare and investment cost and lack of regulatory framework are the factors restraining the growth of the global biological safety testing market during the forecast period.
Geographically, North America accounted for the largest market share in terms of revenue for the biological safety testing market in 2016 followed by Europe. North America is expected to dominate the market during the forecast period. The growth in the region is witnessed owing to adoption of biotechnology in cancer research. Asia Pacific is expected to be the fastest growing region for biological safety testing market during the forecast period due to presence of emerging economies in the region such as China, India and South Korea.
Companies Mentioned
- Avance Biosciences (U.S.)
- Charles River Laboratories (U.S.)
- Cytovance Biologics Inc. (U.S.)
- Lonza Group Ltd. (Switzerland)
- Merck Kgaa (Germany)
- Nordic Scientific And Natural Solutions Ab (Sweden)
- Nuaire (U.S.)
- Pace Analytical Services Inc. (U.S.)
- Paragon Bioservices Inc. (U.S.)
- Sartorius Ag (Germany)
- SGS Sa (Switzerland)
- Source Bioscience (U.K.)
- Thermo Fisher Scientific Inc. (U.S.)
- Toxikon Corporation (U.S.)
- Wuxi Apptec (China)
Key Topics Covered:
1. Introduction
2. Market Overview
3. Market Determinants
4. Market Segmentation
5. Competitive Landscape
6. Geographical Analysis
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/m5pt5f/global_biological
